Taysha Gene Therapies, Inc.
TSHA
$2.31
-$0.07-2.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.52% | -139.35% | 78.20% | 14.92% | -36.54% |
| Total Depreciation and Amortization | -12.92% | -16.94% | -11.18% | -6.12% | -1.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.90% | 104.60% | -91.06% | -46.15% | 73.09% |
| Change in Net Operating Assets | -1,628.86% | 46.35% | 20.20% | -437.94% | 105.96% |
| Cash from Operations | -11.22% | -13.59% | -20.42% | -14.58% | 1.92% |
| Capital Expenditure | -170.00% | 111.76% | -- | -518.75% | 96.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 57.14% | -- | -- | -- |
| Cash from Investing | -165.00% | 230.00% | 99.00% | -518.75% | 96.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 188.46% | -- | -95.22% | 13,996.20% | -48.00% |
| Repurchase of Common Stock | -- | 14.89% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -164.58% | 100.80% | -30.93% | 89.43% | 88.57% |
| Cash from Financing | -136.36% | 91.60% | -95.31% | 18,591.78% | 94.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.44% | 8.46% | -112.63% | 365.85% | 18.38% |